Inventor
KASIBHATLA SHAILAJA
US23 patents
⚠️ This page may combine multiple inventors who share the name “KASIBHATLA SHAILAJA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CYTOVIA INC
12 patentsUS7041685B2May 9, 2006
Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
CYTOVIA INC118 citations96
US6462041B1Oct 8, 2002
Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
CYTOVIA INC44 citations92
US7435750B2Oct 14, 2008
Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
CYTOVIA INC30 citations91
US6613762B2Sep 2, 2003
Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
CYTOVIA INC18 citations89
US6828091B2Dec 7, 2004
Method of identifying immunosuppressive agents
CYTOVIA INC10 citations74
US7176234B2Feb 13, 2007
Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
CYTOVIA INC8 citations73
US6794400B2Sep 21, 2004
4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
CYTOVIA INC7 citations71
US7135480B2Nov 14, 2006
Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis
CYTOVIA INC6 citations59
US7592143B2Sep 22, 2009
Methods of treating diseases responsive to induction of apoptosis and screening assays
CYTOVIA INC3 citations55
US7074813B2Jul 11, 2006
Substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
CYTOVIA INC0 citations51
US7968595B2Jun 28, 2011
Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
CYTOVIA INC0 citations45
US7256219B2Aug 14, 2007
Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof
CYTOVIA INC0 citations39
CELGENE CORP
5 patentsUS11666579B2Jun 6, 2023
Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP2 citations71
US12178822B2Dec 31, 2024
Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion
CELGENE CORP0 citations60
US12396995B2Aug 26, 2025
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CELGENE CORP0 citations57
US11628172B2Apr 18, 2023
Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CELGENE CORP1 citations57
US11583536B2Feb 21, 2023
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CELGENE CORP0 citations57
NOVARTIS AG
4 patentsUS11634497B2Apr 25, 2023
Anti-CCR7 antibody drug conjugates
NOVARTIS AG5 citations69
US10195208B2Feb 5, 2019
Combination therapy
NOVARTIS AG5 citations66
US11752162B2Sep 12, 2023
Compounds and compositions for treating solid tumors by intratumoral administration
NOVARTIS AG1 citations62
US12180291B2Dec 31, 2024
Anti-CCR7 antibody drug conjugates
NOVARTIS AG0 citations57